Impact of the Assumption in Charge of Medical Aid to the Procreation With Donation of Gametes on the Sexuality of the Couple (SEXODON)

July 15, 2020 updated by: Centre Hospitalier Universitaire, Amiens
Sexual disorders associated with medical aid for procreation have already been demonstrated in several studies. However, few of them are interested in the problem of patients in charge of donating gametes, and if studied, it is often restricted to donating sperm to a small number of patients. For this reason, it would be interesting to study the impact of the intake and in charge and the treatments of the Medical Aid to the Procreation on this population of patients (including the patients treated in donation of sperm but also Those supported in oocyte donation)

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Study Type

Observational

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
    • Picardie
      • Amiens, Picardie, France, 80054
        • CHU Amiens Picardie

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients undergoing AMP with donation of gametes whose objective is to detect and evaluate the prevalence of sexual disorders

Description

Inclusion Criteria:

  • Couple, male and female, meeting the legal criteria for access to medically assisted procreation: a couple, a woman under the age of 43, who can testify to a life together. Then breakdown into 3 inclusion groups:

    • Group 1: Patients undergoing AMP with oocyte donation
    • Group 2: couples supported in AMP with sperm donation
    • Group 3: torque supported in intra torque AMP.

Exclusion Criteria:

  • Patients who do not meet the legal criteria for access to the MPA.
  • Patients in charge of Medical Assistance for Procreation "Viral Risk"
  • Patients undergoing medical aid for procreation for pre-existing sexual dysfunction.
  • Patients awaiting embryo reception.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients undergoing AMP with oocyte donation
Other: To evaluate the prevalence of sexual disorders in patients receiving AMP
To evaluate the prevalence of sexual disorders in patients receiving AMP
Couples supported in AMP with sperm donation
Other: To evaluate the prevalence of sexual disorders in patients receiving AMP
To evaluate the prevalence of sexual disorders in patients receiving AMP
Couples supported in AMP intra torque
Other: To evaluate the prevalence of sexual disorders in patients receiving AMP
To evaluate the prevalence of sexual disorders in patients receiving AMP

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Analysis of anonymous sexual well-being questionnaires: one reserved for men, another reserved for women
Time Frame: 1 year
Analysis of anonymous sexual well-being questionnaires: one reserved for men, another reserved for women
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Universitaire, Amiens

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 20, 2017

Primary Completion (Actual)

February 20, 2019

Study Completion (Actual)

February 20, 2019

Study Registration Dates

First Submitted

April 14, 2017

First Submitted That Met QC Criteria

April 27, 2017

First Posted (Actual)

April 28, 2017

Study Record Updates

Last Update Posted (Actual)

July 17, 2020

Last Update Submitted That Met QC Criteria

July 15, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • RNI2016-25 Dr Scheffler

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sexuality

Clinical Trials on To evaluate the prevalence of sexual disorders in patients receiving AMP

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe